GlassScriptPhysician profile
Mark S Zebrowski
NPI 1427010263
$1,719.81
in general payments reported to CMS, 2019-2025
19 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $102 · 2021: $213 · 2022: $240 · 2023: $304 · 2024: $92.79 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738 · Entertainment: $88.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.02 |
| Entertainment | $88.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $448.62 | 2021-2025 | Rocklatan, Simbrinza, Rhopressa |
| Johnson & Johnson Vision Care, INC. | $177.68 | 2019-2022 | |
| Coopervision INC. | $128.28 | 2020-2023 | Cvi Contact Lens |
| Shire North American Group INC | $122.08 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $112.27 | 2021 | |
| Glaukos Corporation | $111.07 | 2025 | Idosetr |
| Biotissue Holdings INC. | $92.03 | 2024-2025 | |
| Optos, INC. | $88.90 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $71.41 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.85 | 2019-2021 | |
| Lensar, INC. | $59.66 | 2020 | |
| Abbvie INC. | $58.39 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $56.20 | 2022-2024 | Vyzulta, Zylet, Lotemax Sm |
| Allergan, INC. | $27.53 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $27.02 | 2022-2023 | Flarex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $21.53 | 2019 | |
| Sight Sciences, INC. | $19.74 | 2025 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $18.20 | 2019 | |
| Santen INC. | $15.35 | 2023 | Verkazia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zebrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.